Robert d. Schreiber, Lloyd j. Old, and Kark J. Smyth (2011). Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science 25 Mar 2011 Vol 331, Issue 6024 pp. 1565-1570.
Yoshiko Iwai, Seigo Terawaki, Tasuku Honjo. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. International Immunology, Volume 17, Issue 2, February 2005, Pages 133–144.
Elsas, A. V., Hurwitz, A. A., & Allison, J. P. (1999). Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation. The Journal of Experimental Medicine, 190(3), 355-366. https://doi.org/10.1084/jem.190.3.355.
Curran, M. A., & Allison, J. P. (2009). Tumor Vaccines Expressing Flt3-Ligand Synergize with CTLA-4 Blockade to Reject Pre-Implanted Tumors. Cancer research, 69(19), 7747. https://doi.org/10.1158/0008-5472.CAN-08-3289.
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., & Allison, J. P. (2017). Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell, 170(6), 1120. https://doi.org/10.1016/j.cell.2017.07.024
